• FCS Express expands the flow cytometry solutions within the Insightful Science platform, enabling world-class data-driven scientific research in academia and biopharma and clinical analysis in regulated enterprise environments.
  • Insightful Science is the leading end-to-end scientific research platform with both the broadest and deepest scientific capabilities across chemistry and biology.
  • The unique platform accelerates innovation and drug discovery by producing a seamless flow of clean and trustworthy data throughout labs.

SAN DIEGO, CA Sept. 14, 2021Insightful Science, the software company enabling the Cloud for Scientific Discovery, announced today that it has completed the transaction to acquire De Novo Software, the maker of FCS Express. FCS Express is the fastest-growing flow cytometry data analysis solution in the industry.

Flow cytometry is a critical laboratory technology and scientific method used throughout the drug development pipeline. FCS Express empowers scientists and researchers to easily extract insights from raw data in less time than any other flow cytometry software. It is easy to use but powerful, intuitive, and rapidly evolving to best meet the demands of modern, digitized scientific workflows.

Insightful Science is a growing portfolio of scientific research and data solutions serving more than 1 million global scientists. The company recently announced the acquisition of Dotmatics, the leading cloud-first platform for scientific research. The combined company forms the Cloud for Scientific Discovery, an end-to-end platform with the world’s leading chemistry and biology solutions serving the broadest set of scientific domains. As a central, unified platform, the company stands apart in its ability to support data-driven research.

By adding FCS Express, Insightful Science further empowers organizations to gain data-driven insights and make decisions in discovery R&D, clinical development, and beyond into bioprocessing and manufacturing.

“We are excited to welcome FCS Express to our growing company,” said Thomas Swalla, CEO of Insightful Science. “The biggest opportunity to accelerate scientific innovation today is to significantly increase the ability to harness valuable insights from data generated in labs. FCS Express is widely-used and trusted software revolutionizing the analysis of flow cytometer data, which is a critical component of modern research. By integrating FCS Express into our Cloud for Scientific Discovery, we help our customers better navigate the transformation to a data-driven culture and accelerate scientific advances that improve the lives of people everywhere.”

“Joining Insightful Science is important to help us achieve our mission to set new standards for the highest-quality and most trustworthy results from flow cytometry analysis,” said Dave Novo, Founder and CEO of De Novo Software. “Our teams share a passion to usher in a new era of fully integrated digital labs that will enable better science and better results to make a meaningful difference.”

FCS Express will continue to be available as a standalone product, as well as have integrations with the Insightful Science platform that will enable world class data-driven scientific research and clinical analysis.

“By deeply understanding our customers’ scientific workflows and data needs, we are uniquely positioned to continue to strengthen our platform by expanding and offering even more comprehensive solutions,” said Brett Ammudsen, CEO Bioinformatics at Insightful Science. With our integration, we take the lead in flow cytometry data analysis, and deliver real value for customers who rely on flow cytometry for facilitating multi-omics analysis to advance medicine in important areas such as immuno-oncology and infectious disease.”

Insightful Science is a privately held portfolio company of Insight Partners, the leading global venture capital and private equity firm investing in high-growth technology and software ScaleUp companies.

For more information, visit www.denovosoftware.com and www.insightfulscience.com.